|
EP2081929B1
(en)
|
2006-11-08 |
2013-01-09 |
Neurocrine Biosciences, Inc. |
Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
|
|
EP3345905B1
(en)
|
2008-09-18 |
2021-09-01 |
Auspex Pharmaceuticals, Inc. |
Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
|
|
WO2011153157A2
(en)
|
2010-06-01 |
2011-12-08 |
Auspex Pharmaceutical, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
WO2012000308A1
(zh)
*
|
2010-06-29 |
2012-01-05 |
中国药科大学 |
丁苯那嗪的拆分方法
|
|
US8351329B2
(en)
*
|
2010-09-14 |
2013-01-08 |
Cisco Technology, Inc. |
Universal load-balancing tunnel encapsulation
|
|
CN102285984B
(zh)
*
|
2010-11-25 |
2012-10-10 |
江苏威凯尔医药科技有限公司 |
(2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
|
|
WO2012081031A1
(en)
*
|
2010-12-15 |
2012-06-21 |
Enaltec Labs Pvt. Ltd. |
Process for preparing tetrabenazine
|
|
EP2897615A4
(en)
|
2012-09-18 |
2016-04-27 |
Auspex Pharmaceuticals Inc |
PHARMACOKINETIC FORMULATIONS OF DEUTERATED BENZOCHINOL INHIBITORS OF THE VESICLE MONOAMINE TRANSPORTER 2
|
|
US9550780B2
(en)
|
2012-09-18 |
2017-01-24 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
US20160068526A1
(en)
|
2013-01-31 |
2016-03-10 |
Auspex Pharmaceuticals, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
WO2015048370A1
(en)
*
|
2013-09-27 |
2015-04-02 |
Auspex Pharmaceuticals, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
EP3424504A1
(en)
*
|
2013-12-03 |
2019-01-09 |
Auspex Pharmaceuticals, Inc. |
Methods of manufacturing benzoquinoline compounds
|
|
MX2016009817A
(es)
*
|
2014-01-27 |
2017-02-28 |
Auspex Pharmaceuticals Inc |
Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
|
|
WO2015120110A2
(en)
|
2014-02-07 |
2015-08-13 |
Auspex Pharmaceuticals, Inc. |
Novel pharmaceutical formulations
|
|
WO2015120317A1
(en)
|
2014-02-07 |
2015-08-13 |
Neurocrine Biosciences, Inc. |
Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
|
|
PE20161573A1
(es)
|
2014-02-13 |
2017-01-19 |
Incyte Corp |
Ciclopropilamina como inhibidor de la lsd1
|
|
KR20240011255A
(ko)
*
|
2014-05-06 |
2024-01-25 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
과다운동성 운동 장애의 치료를 위한 vmat2 억제제
|
|
CN107438606B
(zh)
*
|
2015-02-06 |
2020-09-18 |
纽罗克里生物科学有限公司 |
[9,10-二甲氧基-3-(2-甲基丙基)-1h,2h,3h,4h,6h,7h,11bh-吡啶并-[2,1-a]异喹啉-2-基]甲醇及与其相关的化合物、组合物和方法
|
|
WO2016144901A1
(en)
|
2015-03-06 |
2016-09-15 |
Auspex Pharmaceuticals, Inc. |
Methods for the treatment of abnormal involuntary movement disorders
|
|
PE20180455A1
(es)
|
2015-04-03 |
2018-03-05 |
Incyte Corp |
Compuestos heterociclicos como inhibidores de lsd1
|
|
MX390795B
(es)
*
|
2015-06-23 |
2025-03-21 |
Neurocrine Biosciences Inc |
Inhibidores de transportador de monoamina vesicular tipo 2 (vmat2) para tratar enfermedades o trastornos neurologicos.
|
|
SG10202001219UA
(en)
|
2015-08-12 |
2020-03-30 |
Incyte Corp |
Salts of an lsd1 inhibitor
|
|
WO2017060870A1
(en)
|
2015-10-09 |
2017-04-13 |
Hermann Russ |
Combination of deuterated levodopa with carbidopa and opicapone for the treatment of parkinson`s disease
|
|
CN115304596A
(zh)
*
|
2015-10-30 |
2022-11-08 |
纽罗克里生物科学有限公司 |
Valbenazine盐及其多晶形物
|
|
SI3394057T1
(sl)
|
2015-12-23 |
2022-06-30 |
Neurocrine Biosciences, Inc. |
Sintetičen postopek za pripravo (S)-(2R,3R,11bR)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1H- pirido(2,1,-a)izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata)
|
|
WO2017182916A1
(en)
*
|
2016-04-22 |
2017-10-26 |
Lupin Limited |
Novel process for preparation of tetrabenazine and deutetrabenazine
|
|
US10442800B2
(en)
*
|
2016-06-29 |
2019-10-15 |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
Crystal forms of NBI-98854, preparation method and use thereof
|
|
WO2018067945A1
(en)
*
|
2016-10-06 |
2018-04-12 |
Assia Chemical Industries Ltd. |
Solid state forms of valbenazine
|
|
WO2018102673A1
(en)
|
2016-12-02 |
2018-06-07 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating schizophrenia or schizoaffective disorder
|
|
WO2018130345A1
(en)
|
2017-01-10 |
2018-07-19 |
Sandoz Ag |
Crystalline valbenazine free base
|
|
MY199695A
(en)
*
|
2017-01-27 |
2023-11-18 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2018153632A1
(en)
|
2017-02-27 |
2018-08-30 |
Sandoz Ag |
Crystalline forms of valbenazine salts
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
KR20230003308A
(ko)
|
2017-03-15 |
2023-01-05 |
오스펙스 파마슈티칼스, 인코포레이티드 |
듀테트라베나진의 유사체, 이의 제조 및 용도
|
|
GB201705303D0
(en)
*
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
CN110691596A
(zh)
*
|
2017-04-01 |
2020-01-14 |
阿德普蒂奥制药有限公司 |
药物组合物
|
|
GB201705305D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705306D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705302D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705304D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
JOP20190239A1
(ar)
|
2017-04-19 |
2019-10-09 |
Neurocrine Biosciences Inc |
مركبات مثبطة لـ vmat2 وتركيبات منها
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
DK3684333T3
(da)
|
2017-09-21 |
2025-05-12 |
Neurocrine Biosciences Inc |
Valbenazin-formulering med høj dosis og sammensætninger, fremgangsmåder og kits relateret hertil
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
US20200230127A1
(en)
|
2017-10-10 |
2020-07-23 |
Neurocrine Biosciences, Inc. |
Methods for the Administration of Certain VMAT2 Inhibitors
|
|
RU2020114598A
(ru)
|
2017-11-08 |
2021-12-09 |
Фореси Фармасьютикалс Ко., Лтд. |
Сложные эфиры дигидротетрабеназина
|
|
US11384077B2
(en)
|
2017-11-22 |
2022-07-12 |
Assia Chemical Industries Ltd. |
Solid state form of Valbenazine
|
|
JP7212958B2
(ja)
|
2017-12-26 |
2023-01-26 |
▲蘇▼州科睿思制▲葯▼有限公司 |
バルベナジントシル酸塩の結晶形及びその製造方法並びに用途
|
|
CN110092785A
(zh)
*
|
2018-01-31 |
2019-08-06 |
广东东阳光药业有限公司 |
一种丁苯那嗪的动态拆分方法
|
|
GB201808464D0
(en)
|
2018-05-23 |
2018-07-11 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compounds for use in treating huntington's disease
|
|
MX2020013004A
(es)
|
2018-06-14 |
2021-02-17 |
Neurocrine Biosciences Inc |
Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
|
|
BR112021000019A2
(pt)
|
2018-08-15 |
2021-04-06 |
Neurocrine Biosciences Inc. |
Métodos para administração de certos inibidores de vmat2
|
|
WO2020047198A1
(en)
|
2018-08-31 |
2020-03-05 |
Incyte Corporation |
Salts of an lsd1 inhibitor and processes for preparing the same
|
|
EP3860599B1
(en)
|
2018-10-04 |
2024-05-15 |
Adeptio Pharmaceuticals Limited |
(+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
|
|
CA3065236A1
(en)
|
2018-12-27 |
2020-06-27 |
Apotex Inc. |
Novel crystalline form of valbenazine dibesylate
|
|
WO2020213014A1
(en)
|
2019-04-19 |
2020-10-22 |
Mylan Laboratories Limited |
An improved process for the preparation of valbenazine and its salts
|
|
US10689380B1
(en)
|
2019-07-30 |
2020-06-23 |
Farmhispania S.A. |
Crystalline forms of valbenazine ditosylate
|
|
US12565495B2
(en)
*
|
2019-08-12 |
2026-03-03 |
Luye Innomind Pharma Shijiazhuang Co., Ltd. |
VMAT2 inhibitor and preparation method therefor and application thereof
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
CN117736203A
(zh)
|
2019-09-13 |
2024-03-22 |
纽罗克里生物科学有限公司 |
用于合成缬苯那嗪的方法
|
|
CN110698397A
(zh)
*
|
2019-10-28 |
2020-01-17 |
南京红杉生物科技有限公司 |
丁苯那嗪中间体及其合成方法、应用和合成用中间产物
|
|
AR125188A1
(es)
|
2021-03-22 |
2023-06-21 |
Neurocrine Biosciences Inc |
Inhibidores del vmat2 y métodos de uso
|
|
WO2022232060A1
(en)
|
2021-04-26 |
2022-11-03 |
Neurocrine Biosciences, Inc. |
Processes for the synthesis of valbenazine
|
|
EP4362944A1
(en)
|
2021-06-30 |
2024-05-08 |
Neurocrine Biosciences, Inc. |
Valbenazine for use in the add-on treatment of schizophrenia
|
|
MX2023014977A
(es)
|
2021-06-30 |
2024-02-09 |
Neurocrine Biosciences Inc |
Valbenazina para usarse en el tratamiento de discinesia debido a paralisis cerebral.
|
|
IL315181A
(en)
|
2022-03-07 |
2024-10-01 |
Neurocrine Biosciences Inc |
Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
|
|
CN119907800A
(zh)
|
2022-09-21 |
2025-04-29 |
纽罗克里生物科学有限公司 |
六氢-2H-吡啶并[2,1-a]异喹啉VMAT2抑制剂及其使用方法
|
|
WO2025038959A1
(en)
|
2023-08-17 |
2025-02-20 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025038938A1
(en)
|
2023-08-17 |
2025-02-20 |
Neurocrine Biosciences, Inc. |
Valbenazine for use in the treatment of huntington's chorea
|
|
WO2025096823A1
(en)
|
2023-11-01 |
2025-05-08 |
Neurocrine Biosciences, Inc. |
Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
|
|
WO2025188830A1
(en)
|
2024-03-06 |
2025-09-12 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025199234A1
(en)
|
2024-03-20 |
2025-09-25 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors and methods of use
|
|
WO2026050236A1
(en)
|
2024-08-27 |
2026-03-05 |
Neurocrine Biosciences, Inc. |
Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder
|